ArticleCurrent addiction reports2025
The Potential Utility of GLP-1 Receptor Agonist Medications for Addiction Treatment: A Narrative Review of Clinical and Epidemiological Evidence.
Article in Current addiction reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.Addictive behaviors reports · 2026Article
- Repeated semaglutide treatment attenuates cocaine-vs-food choice in male and female rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial.BMJ open · 2026Article
- GLP-1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review.Alcohol, clinical & experimental research · 2026Review
- Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review.bioRxiv : the preprint server for biology · 2026Article
- Strategic approaches to reducing the substance use-related burden of disease in Canada.Lancet regional health. Americas · 2026Article
- An interoceptive model of energy allostasis linking metabolic and mental health.Science advances · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Purpose of Review: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a potential therapeutic class for substance use disorders (SUD). This narrative review focuses primarily on clinical and epidemiological studies to synthesize existing evidence on GLP-1RAs in the context of SUD. The overall objective is to clarify current understanding, summarize ongoing and forthcoming trials, and provide directions for future clinical research on the potential utility of GLP-1RAs in treating SUD. Recent Findings: Among addictive substances, alcohol has received the most attention in GLP-1RA research. Nicotine, opioids, and psychostimulants have also been investigated. Large-scale retrospective cohort studies provide evidence supporting improvements in substance use-related outcomes with GLP-1RA treatment. Evidence from randomized controlled trials (RCTs) of GLP-1RAs for SUD is beginning to accumulate, with some variability in findings, potentially due to heterogeneity in GLP-1RAs and study populations. Additional data from RCTs will be essential to determine the efficacy, safety, and tolerability of GLP-1RAs for treating SUD. Summary: Converging evidence suggests that GLP-1RAs hold promise for addiction treatment, highlighting the need for RCTs to establish whether GLP-1RAs can expand the range of treatment options for SUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.